Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
JSPR
JSPR | US
0.93
USD0.01
1.46%
JSPR | US
About JSPR
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
0.93
Open
0.94
High
0.96
Low
0.85
Jasper Therapeutics Inc. a clinical-stage biotechnology company develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases such as chronic spontaneous urticaria lower to intermediate risk myelodysplastic syndrome and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City California.
View LessJSPR | US
Risk
129.9
Sharpe
-0.80
Luna's Score
45/100
Recommendation
Sell
Luna says (JSPR | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
150.2%1 month
129.9%3 months
89.9%6 months
89.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.02
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
-3.42
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-67.01M
MarketCap
14.08M
MarketCap(USD)
14.08M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-59.32
Short ratio
6.46
Short perc.
10.02
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.33
Range1M
0.64
Range3M
1.04
Volumes: Market Activity
Rel. volume
0.88
Price X volume
496.13K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.42 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.02 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 89.86 | - | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 14.08M | - | Emerging |
